Navigation Links
Magnetic nanoparticles navigate therapeutic genes through the body
Date:3/5/2009

Health professionals send genes and healthy cells on their way through the bloodstream so that they can, for example, repair tissue damage to arteries. But do they reach their destination in sufficient quantities? Scientists of the PTB have developed a highly sensitive measuring method with which the efficiency of this therapy can be investigated: Small magnetic particles which are situated on the planted gene or on the planted cell can with the aid of an external magnetic field be specifically directed to the location of the damage. There the researchers determine, accurate to the picogram per cell, the quantity of the magnetic material and thus also the quantity of the therapeutically effective genes or cells. In a joint study with the University of Bonn it became clear: By means of the magnetic method it is possible to dramatically increase the efficiency of the gene transfer in comparison to the non-magnetic method.

Magnetic nanoparticles can support or even enable gene transfer under clinically relevant experimental conditions. For the transduction of human cells, gene carriers were coupled to magnetic nanoparticles and dragged into the cells by magnetic field gradients. The efficiency of magnetic transduction turned out to be much higher than the nonmagnetic procedure. An additional welcome side effect is the "magnetization" of the cells after the incorporation of nanoparticles. This may enable the targeted transport of the cells to regions of interest.

A closer look at the underlying mechanism of magnetic gene transfer was taken by the quantification of the magnetic material that was delivered to the cells. The required highly sensitive measurements in the range of a few picogramm per cell were made by PTB using magnetorelaxometry. The good correlation between measurement data and gene transfer encourages to use magnetorelaxometry for monitoring the efficiency of gene and cell transfer, possibly even in vivo.


'/>"/>

Contact: Dr. Lutz Trahms
Lutz.Trahms@ptb.de
49-303-481-7213
Physikalisch-Technische Bundesanstalt (PTB)
Source:Eurekalert

Page: 1

Related biology news :

1. Magnetic snakes control fluids, gravity-defying droplets, and solving a dragonfly mystery
2. Do migratory birds see the magnetic field?
3. New magnetic separation technique might detect multiple pathogens at once
4. New system would use rotating magnetic field to detect pathogens
5. UVa biomedical engineering study shows magnetic field can reduce swelling
6. Biomagnetics developed for use in new breast cancer tests
7. Researchers mimic bacteria to produce magnetic nanoparticles
8. Caltech geobiologists discover unique magnetic death star fossil
9. Electromagnetic phantom exorcises specters of metal detector tests
10. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
11. MIT: Remote-control nanoparticles deliver drugs directly into tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6